D37.039 Insurance Policy Changes

ICD-10 D37.039 is officially defined as "Neoplasm of uncertain behavior of the major salivary glands, unspecified." code D37.039 is referenced in 5 tracked payer policy changes from Blue Cross Blue Shield of North Dakota. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D37.039 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross Blue Shield of North Dakota · Identified Jun 19, 2026High impact
Pharmacy Policy Updates
Blue Cross Blue Shield of North Dakota revised many Commercial prior authorization drug policies, with revisions effective April 14, 2026, including oncology drugs such as Adcetris, Keytruda IV, Keytruda SQ, Opdivo IV, Opdivo SQ, Darzalex IV and Trodelvy. The same notice lists Commercial post service claim edit policy revisions effective March 1, 2026 for Aranesp, Epoetin alfa and Mircera, and Commercial medical drug coding updates effective April 1, 2026 with new, removed and changed HCPCS codes.
Blue Cross Blue Shield of North Dakota · Effective Sep 9, 2026Medium impact
Pharmacy Policies Available Online
Blue Cross Blue Shield of North Dakota updated its commercial pharmacy policies, and the revisions to the commercial prior authorization medical drug policies are effective September 9, 2026. Revisions to the commercial post service claim edit medical drug policies are effective August 1, 2026. Many of the prior authorization policies now state the number of days allowed for initial and renewal authorization durations, replace specific contraindications in the Universal Criteria with general language that the member does not have any FDA contraindications, and add covered ICD-10 diagnosis codes in Appendix 1.
Blue Cross Blue Shield of North Dakota · Effective Aug 11, 2026Medium impact
Pharmacy Policy Updates
Blue Cross Blue Shield of North Dakota revised many Commercial prior authorization medical drug policies, with revisions effective August 11, 2026. Changes include new indications such as Enhertu for HER2-positive early-stage breast cancer, Bizengri for NRG1 gene fusion biliary tract cancer and Ocrevus IV for pediatric relapsing-remitting multiple sclerosis, along with new ICD-10 codes for breast, biliary and other cancers. The Portrazza policy is being retired, and Commercial post service claim edit policies had revisions effective July 1, 2026, including ICD-10 codes H25.11 and H25.12 added to Dextenza.
Blue Cross Blue Shield of North Dakota · Effective May 12, 2026Medium impact
Pharmacy Policy Updates
Blue Cross Blue Shield of North Dakota revised many Commercial prior authorization medical drug policies, with revisions effective May 12, 2026. Changes include new indications such as Darzalex SQ for newly diagnosed multiple myeloma, Keytruda IV and SQ for platinum-resistant ovarian cancer, and management of CAR T-cell and lymphocyte engager-related toxicities for several drugs, along with length of authorization updates, new ICD-10 codes and HCPCS code changes.
Blue Cross Blue Shield of North Dakota · Effective Mar 17, 2026Medium impact
Pharmacy Policies Available Online
Commercial prior authorization medical drug policies have revisions effective March 17, 2026, with many policies adding the Appendix A NQTL Factor Checklist, showing the number of days allowed for authorization durations, and replacing 'coverage' with 'prior authorization validity' in the initial and renewal criteria. Clinical updates include Eylea HD for macular edema following retinal vein occlusion, Breyanzi for relapsed or refractory marginal zone lymphoma, and new appendiceal neoplasm and cancer indications with ICD-10 codes D37.3 and Z85.038. Commercial post service claim edit policies for Trogarzo have revisions effective Feb. 1, 2026.

Watch D37.039

Get one email when a payer policy names D37.039, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code D37.039?

There are 5 tracked policy changes affecting code D37.039, including updates from Blue Cross Blue Shield of North Dakota. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code D37.039?

Payers that have issued tracked updates for code D37.039 include: Blue Cross Blue Shield of North Dakota.

How do I get notified when code D37.039 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code D37.039. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code D37.039?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pharmacy Policy Updates

Pharmacy Policies Available Online

Pharmacy Policy Updates

Pharmacy Policy Updates

Pharmacy Policies Available Online

What insurance policy changes affect code D37.039?

Which payers have updated policy for code D37.039?

How do I get notified when code D37.039 policy changes?

Why do payers change policies for code D37.039?